Market Overview

Myomo Announces Continued Momentum Across Europe

Share:

With the appointment of industry veteran, John Frijters, a
distribution partnership with Bandagist Jan Nielsen, and assistance from
The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust

Myomo,
Inc.
 (NYSE:MYO) ("Myomo" or the "Company"), a wearable
medical robotics company, today announced continued momentum across
Europe with the appointment of John Frijters as Business Development
Manager for EU, a distributor agreement with Bandagist Jan Nielsen to
deliver MyoPro to patients across Denmark and the first screening day in
the United Kingdom.

"We estimate the number of patients in the EU who could benefit from
MyoPro is well over a million people," says Jon Naft, Myomo VP and
General Manager. "We believe that the European market will be an
important part of the MyoPro business in the long term, so we are
establishing these strategic footholds."

Paul R. Gudonis, Chairman and CEO of Myomo, said, "This announcement
reaffirms Myomo's commitment to helping restore function in the arms and
hands of individuals who are suffering from the effects of a
neuromuscular disease or injury. We are looking forward to providing
more individuals a chance to improve their quality of life."

Background on John Frijters

Myomo announces the appointment of John Frijters as Business Development
Manager for Europe. John will be responsible for managing Myomo's
relationship with existing distribution partners and establishing
additional distributors throughout the EU.

Prior to joining Myomo, John Frijters worked for ReWalk Robotics in the
position of V.P. Sales & Business Development Europe from 2010 to
2018. Before ReWalk, John served as V.P. of Global Sales and Marketing
at Stryker-Berchtold, and spent most of his professional career in
various roles with Ottobock, a manufacturer and supplier of a range of
healthcare products including prosthetics, orthotics, rehabilitation
technology and mobility products.

"I am honored to join the Myomo team as Business Development Manager,"
said John Frijters. "Throughout my career, I've enjoyed working with
multi-national teams in the field of non-invasive medical devices and
medical products, and I am looking forward to bringing my knowledge,
network and expertise to Myomo."

Distribution Contract

Bandagist Jan Nielsen and Myomo have signed a distribution contract to
help bring MyoPro to patients in the Nordic region. Headquartered in
Copenhagen Denmark, Bandagist Jan Nielsen was founded and is currently
owned by Jan Nielsen (CPO). Nielsen has a team of bandagists,
physiotherapists, specialized technicians, (CO, CPO's) and shop
assistants that manage the patient care needs on orthosis and prosthesis
and other medical aids. The team also offers patients in-home visits.

"Myomo's leading technology is now available in Denmark, and the MyoPro
completes our offer to the many Danish people that lost the capability
to use their hand and arm following a stroke or a brachial plexus
injury," said Jan Nielsen, CPO and CEO of Bandagist Jan Nielsen.
"Myomo's products together with Bandagist Jan Nielsen A/S presents a
great solution for the many Danish people that need this innovative
orthotic technology."

The company employs 45 employees at two locations in Kopenhagen
(Frederiksborggade and Sundholmsvej) and has clinic sessions at
satellite clinics in Sjæland and Føun.

Bandagist Jan Nielsen and Myomo attended the 11th Nordic
Prosthetist and Orthotist Conference in Copenhagen September 6-8, 2018.

First Screening Day in the United Kingdom

Myomo conducted the first ever MyoPro free screening day in the United
Kingdom with Robert Jones and Agnes Hunt Orthopaedic Hospital NHS
Foundation Trust and Hobbs Rehabilitation. Held on September 4, 2018,
the screenings gave potential users a convenient chance to be evaluated
by clinical specialists to determine if the MyoPro might help them
overcome upper-limb paralysis caused by stroke, brachial plexus injury
or other neuromuscular disease or injury. Ten attended and eight were
qualified. Myomo has seen good success with screening days across the
United States and is continuing to educate and assist more individuals,
families, physicians, and therapists about the benefit of the MyoPro
myoelectric orthosis.

"We have spent ten years looking for a myoelectric elbow brace to
restore arm and hand function to our paralyzed patients and have finally
found it in MyoPro" said Mr. Simon Pickard, Consultant Orthopaedic
Surgeon at Robert Jones & Agnes Hunt Orthopaedic & District Hospital NHS
Trust. "These screening days make it very convenient for clinicians to
evaluate patients and prescribe the device."

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers expanded
mobility for those suffering from neurological disorders and upper limb
paralysis. Myomo develops and markets the MyoPro product line. MyoPro is
a powered upper limb orthosis designed to support the arm and restore
function to the weakened or paralyzed arms of patients suffering from
CVA stroke, brachial plexus injury, traumatic brain or spinal cord
injury, ALS or other neuromuscular disease or injury. It is currently
the only marketed device that, sensing a patient's own EMG signals
through non-invasive sensors on the arm, can restore an individual's
ability to perform activities of daily living, including feeding
themselves, carrying objects and doing household tasks. Many are able to
return to work, live independently and reduce their cost of care. Myomo
is headquartered in Cambridge, Massachusetts, with sales and clinical
professionals across the U.S. and distribution partners in Europe. For
more information, please visit www.myomo.com.

Forward Looking Statements

This press release contains forward-looking statements regarding the
Company's future business expectations including with respect to the
Company's plans and expectations for the European market, which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are only
predictions and may differ materially from actual results due to a
variety of factors. Our actual results could differ materially from
those anticipated in these forward looking statements for many reasons,
including, without limitation, risks related to regulatory approval and
market acceptance of our products, and the other risk factors contained
in our filings made with the Securities and Exchange Commission. More
information about factors that potentially could affect Myomo's
financial results is included in Myomo's filings with the Securities and
Exchange Commission. The Company cautions readers not to place undue
reliance on any such forward-looking statements, which speak only as of
the date made. The Company disclaims any obligation subsequently to
revise any forward-looking statements to reflect events or circumstances
after the date of such statements or to reflect the occurrence of
anticipated or unanticipated events.

View Comments and Join the Discussion!